{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:04:56Z","timestamp":1792461896011,"version":"4.5.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die diabetische Retinopathie (DR) ist die h\u00e4ufigste Ursache f\u00fcr schwere Sehbehinderung und Erblindung im erwerbst\u00e4tigen Alter. Eine subjektive Beeintr\u00e4chtigung des Sehverm\u00f6gens tritt h\u00e4ufig erst in fortgeschrittenen Stadien der DR ein. Daher sind Screening-Ma\u00dfnahmen asymptomatischer Patienten und eine stadiengerechte Behandlung essenziell. Dieser Beitrag gibt einen praxisbezogenen \u00dcberblick \u00fcber diagnostische und therapeutische Prinzipien der nicht-proliferativen und proliferativen Form.<\/jats:p>","DOI":"10.1055\/a-1545-9927","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T18:39:27Z","timestamp":1628707167000},"page":"1143-1159","source":"Crossref","is-referenced-by-count":25,"title":["Diabetische Retinopathie"],"prefix":"10.1055","volume":"238","author":[{"given":"Teresa","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00347-016-0315-8","article-title":"Nationale Versorgungsleitlinie (NVL) Diabetische Retinopathie","volume":"113","author":"F Ziemssen","year":"2016","journal-title":"Ophthalmologe"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3238\/arztebl.2016.0816","article-title":"Pr\u00e4vention und Therapie von Netzhautkomplikationen bei Diabetes","volume":"113","author":"G S Schorr","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2515841420950513","article-title":"Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema","volume":"12","author":"A Markan","year":"2020","journal-title":"Ther Adv Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"J G Gross","year":"2015","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-Year Outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"J G Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40662-020-00182-7","article-title":"Different fundus imaging modalities and technical factors in AI screening for diabetic retinopathy: a review","volume":"7","author":"G Lim","year":"2020","journal-title":"Eye Vis (London)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"S Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"J WY Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40664-015-0082-4","article-title":"Diabetische Retinopathie","volume":"66","author":"N Sch\u00f6ffel","year":"2016","journal-title":"Zentralbl Arbeitsmed"},{"key":"ref10","volume-title":"Diabetische Retinopathien","author":"T Barth","year":"2021","edition":"2. Aufl."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11428-020-00642-7","article-title":"Diabetes Update 2020: das Wichtigste f\u00fcr die \u00e4rztliche Praxis","volume":"16","author":"W A Scherbaum","year":"2020","journal-title":"Diabetologe"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00347-020-01116-3","article-title":"Erg\u00e4nzende Stellungnahme der DOG, der RG und des BVA zur Therapie der proliferativen diabetischen Retinopathie","volume":"117","author":"Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft e. V. (RG)","year":"2020","journal-title":"Ophthalmologe"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s11428-018-0417-9","article-title":"Klinische Stadieneinteilung der diabetischen Retinopathie","volume":"14","author":"F Ziemssen","year":"2018","journal-title":"Diabetologe"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s11428-018-0414-z","article-title":"Therapie der proliferativen diabetischen Retinopathie","volume":"14","author":"N Bornfeld","year":"2018","journal-title":"Diabetologe"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1755-3768.2008.01355.x","article-title":"Bevacizumab as adjuvant for neovascular glaucoma","volume":"88","author":"J Beutel","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/bjo.87.10.1258","article-title":"Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy","volume":"87","author":"P H Scanlon","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.22608\/APO.201976","article-title":"Artificial intelligence in diabetic eye disease screening","author":"C Y Cheung","year":"2019","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2016.17216","article-title":"Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs","volume":"316","author":"V Gulshan","year":"2016","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/IAE.0000000000002487","article-title":"Detection of clinically unsuspected retinal neovascularization with wide-field optical coherence tomography angiography","volume":"40","author":"Q S You","year":"2020","journal-title":"Retina"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic Retinopathy Preferred Practice Pattern","volume":"127","author":"C J Flaxel","year":"2019","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1900\/RDS.2015.12.159","article-title":"Biomarkers in diabetic retinopathy","volume":"12","author":"A J Jenkins","year":"2015","journal-title":"Rev Diabet Stud"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00347-017-0605-9","article-title":"OCT-Angiographie bei der diabetischen Maculopathie","volume":"115","author":"S Henke","year":"2018","journal-title":"Ophthalmologe"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/bjophthalmol-2017-311489","article-title":"Automated diabetic retinopathy detection using optical coherence tomography angiography: a pilot study","volume":"102","author":"H S Sandhu","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00417-018-3992-y","article-title":"Comparison between wide-angle OCT angiography and ultra-wide field fluorescein angiography for detecting non-perfusion areas and retinal neovascularization in eyes with diabetic retinopathy","volume":"256","author":"O Sawada","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/a-1416-5619","article-title":"Diabetisches Makula\u00f6dem","volume":"11","author":"T Barth","year":"2021","journal-title":"Augenheilkunde up2date"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-18021-7","volume-title":"Retinale Gef\u00e4\u00dferkrankungen","author":"A Joussen","year":"2012"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group \u2013 ETDRS","year":"1991","journal-title":"Ophthalmology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti-vascular endothelial growth factor vs. sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The Protocol W Randomized Clinical Trial","author":"R K Maturi","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"08","key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011234","article-title":"Laser photocoagulation for diabetic retinopathy","author":"J R Evans","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS Report Number 8","volume":"88","author":"Diabetic Retinopathy Study Research Group \u2013 DRS","year":"1981","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00347-019-01015-2","article-title":"Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makula\u00f6dems: Stand August 2019","volume":"117","author":"Deutsche Ophthalmologische Gesellschaft (DOG)","year":"2020","journal-title":"Ophthalmologe"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"R L Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"J A Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ophtha.2014.08.048","article-title":"Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy","volume":"122","author":"M S Ip","year":"2015","journal-title":"Ophthalmology"},{"issue":"11","key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008721.pub2","article-title":"Anti-vascular endothelial growth factor for proliferative diabetic retinopathy","author":"M J Martinez-Zapata","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","article-title":"Effect of intravitreous aflibercept vs. vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: A randomized clinical trial","volume":"324","author":"A N Antoszyk","year":"2020","journal-title":"JAMA"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1545-9927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T19:38:24Z","timestamp":1634585904000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1545-9927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,18]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1545-9927","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]}}}